National and Kapodistrian University of Athens
Η εκτίμηση της επίδρασης της ενδοφθάλμιας χρήσης της ranibizumab στην αρτηριακή υπέρταση και στην αρτηριακή σκληρία σε ασθενείς με ηλικιακή εκφύλιση ωχράς κηλίδας
Abstract
dc:descriptionIntroduction: Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in developed countries. There are two types of AMD, the dry (atrophic) and wet (neovascular or exudative). Wet AMD is a type of advanced AMD that is characterized by pathologic proliferation and leakage of the abnormal blood vessels. Exaggerated endothelial dysfunction, chronic inflammation and oxidative stress have all been linked to the pathogenesis of this disease. Aortic stiffness and systemic inflammation are independent predictors of cardiovascular risk. Although the pathogenesis of neovascular AMD is not completely known, vascular endothelial growth factor (VEGF) is identified as a major stimulus of abnormal neovascularization. Anti-VEGF, injected intravitreally, can reverse the course of exudative AMD. At present, no specific and reliable marker has been found to aid monitoring the response to anti-VEGF therapy. Aim: To investigate the prolonged effect of therapy with ranibizumab injections on aortic stiffness, arterial pressure and systemic inflammatory activation and the association of changes in these systemic biomarkers with macular morphology response to therapy. Methods: 54 patients (mean age: 76±10 years) with newly diagnosed wet AMD received three consecutive monthly intravitreal injections of ranibizumab (0.5mg) (initial loading dose). BP and carotid-femoral pulse wave velocity (PWV) were measured at baseline (approximately 2 days before the first injection), 24 h after the first and second injection (time interval between the injections: 1 month) and 1 month after the third injection. High sensitivity interleukin-6 (hsIL-6) levels in serum were measured at three time points (baseline, 24 h after the first injection and 1 month after the third injection). Serum creatinine, fasting blood glucose and lipid levels were measured at baseline and 1 month after the third injection. The response to ranibizumab injections was examined according to both functional and anatomical criteria, after ophthalmological exam.Results: Ranibizumab caused a decrease of PWV after the first (by 0.36±1.4 m/s) and the second injection (by 0.31±1.4 m/s) and remained decreased 1 month after the third injection (overall P<0.05). PWV decreased significantly in good responders (according to clinical criteria and fundus findings, P=0.004), whereas it increased numerically in poor responders (P=0.21) over the study period. In responders, hsIL-6 decreased after the first injection and remained decreased 1 month after the third injection (by 0.63±0.35 pg/ml, overall P=0.02). PWV (P=0.005) and hsIL-6 (P=0.042) were independent predictors of improvement after adjusting for age and presence of hypertension and diabetes. The decrease in PWV through the whole study period was positively correlated with the reduction in hsIL-6 (r=0.36, P<0.01).Conclusion: Intravitreal ranibizumab injections lead to a decrease in PWV and hsIL-6. Both parameters predict clinical improvement and may aid to improving treatment targeting and hence therapeutic outcome in patients with AMD.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gourgouli, Ioanna
- Γουργούλη, Ιωάννα
Subjects
dc:subject × 15- Αρτηριακή σκληρία
- Ηλικιακή εκφύλιση ωχράς κηλίδας
- ranibizumab
- Ιντερλευκίνη-6 (IL-6)
- Arterial stiffness
- Age-related macular degeneration
- Interleukin 6 (IL-6)
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Οφθαλμολογία
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Ophthalmology
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51924